Custom service
Host Cell Protein Mitigation
Driving residual HCP down without losing yield.
Host cell proteins are the impurity that hides until the assay that measures them exists. A preparation can pass SDS-PAGE and SEC with a clean profile while carrying hundreds of nanograms of HCP per milligram of product, and the consequences appear downstream: immunogenicity in therapeutic contexts, interference in cell assays, instability from co-purified host proteases. Mitigation is a process development task, not a polishing afterthought.
Development starts with measurement. A platform-specific or process-specific HCP ELISA establishes the baseline, and — more informative than the total — the HCP profile by mass spectrometry identifies which host proteins are actually present. The difficult ones are known: PLBL2 in CHO, HSP70 family members, endogenous host enzymes that bind the product or the capture resin. Each has a removal behaviour, and the polishing train is designed around the ones present rather than around a generic protocol.
The polishing train is then developed iteratively. Ion exchange at the pH where the product and the problem HCPs separate, hydrophobic interaction where charge fails, mixed-mode resins where both fail, and affinity steps where the product tolerates them. Each step's HCP clearance is measured with its yield, because a step that clears 90% of HCP and costs 30% of product is usually the wrong step. The result is a documented train with clearance factors, yield and mass balance per step.
HCP mitigation is required for products heading toward regulated use, for materials used in sensitive cell assays, and for proteins whose stability is compromised by co-purified host enzymes.
It cannot help when the HCP burden originates upstream — a capture step that binds host protein is fixed at the capture step, and polishing an over-loaded capture is the expensive way to learn that.
The campaign report carries HCP ELISA values, mass spectrometric HCP profiles before and after, per-step clearance factors and yields, residual DNA where measured, and the full process conditions. A retention sample is held for verification.
Service Highlights
- Profile before protocol. HCP identified by mass spectrometry so the train targets the proteins actually present, including the known difficult ones.
- Platform and process-specific assays. HCP ELISA matched to the expression host, with coverage documented.
- Clearance with yield. Each polishing step's HCP reduction and product recovery measured together, so the train is optimised for both.
- Difficult HCP handled. PLBL2, HSP70 and resin-binding host proteins addressed with specific strategies rather than generic polishing.
- Mass balance documented. HCP, product and yield tracked across every step.
- Transferable train. The developed process documented with conditions and resin details for in-house adoption.
How the work runs
Baseline measurement
HCP ELISA and mass spectrometry profile establish which host proteins are present and at what level.
Target setting
The required HCP level agreed against the product's application and regulatory context.
Polishing train design
Steps selected against the HCP profile and the product's charge and hydrophobic behaviour.
Iterative development
Each step run and measured for HCP clearance and yield; the train revised where a step underperforms.
Combined verification
Full train executed; total HCP reduction, yield and product quality measured.
Documentation
Process report with per-step clearance factors, mass balance and transfer documentation.
Specifications & timeline
- Expression hosts
- CHO, HEK293, E. coli, insect, yeast
- Assays
- Host-specific HCP ELISA, residual DNA, mass spectrometry HCP profiling
- Methods
- Ion exchange, HIC, mixed-mode, affinity, membrane adsorbers
- Target levels
- Down to <100 ng HCP per mg product, application-dependent
- Timeline
- 4–8 weeks per development campaign
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.